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Risk of Transfusion-Transmitted Human T-Cell 
Lymphotropic Virus-Tfrpe I in Latin America 
Eduardo Gotuzzo, MD* 
In a recent publication, G. Schmunis et al presented data 
from Latin America on blood quality and on important 
approaches to preventing human immmunodeficiency 
virus (HIV), acquired immunodeficiency syndrome 
(AIDS), and other infectious diseases that may be trans- 
mitted by blood transfusion.’ Mass screening between 
1987 and 1988 in Peru of blood from more than 90,000 
donors highlighted potential problems in the donor pop- 
ulation, and it also uncovered inappropriate practices 
related to the use of blood transfusions.2 Since then, ade- 
quate screening of the blood supply for HIV was imple- 
mented and new transfusion-related AIDS cases have been 
prevented during the past 8 years. 
An earlier review assessed blood transfusions and the 
risks of transmitting HIV hepatitis B, hepatitis C, syphilis, 
and Chagas’ disease.’ Another important pathogen that 
should be considered when discussing blood transfusion 
in Latin America is human T-cell lymphotropic virus-type 
I (HTLV-I). 
Transfusions with HTLV-I-contaminated whole blood, 
platelets, or packed red cells infects 50 to 70% of 
recipients. Transmission rates are highest with recently 
donated blood (< 1 wk). The virus is not transmitted 
through blood products such as fresh frozen plasma or 
cryoprecipitates. 
Human T-cell lymphotropic virus-type I infection 
has been reported at rates as high as 15% among peo- 
ple of Japanese ancestry in Bolivia, Brazil, and Peru.3,4 
Among Latin Americans of African descent, seroposi- 
tivity rates for HTLV-I have been reported to be 3 to 
lo%, and among other ethnic groups, such as the 
Quachuas, 2 to 5%.5,” Seropositivity rates of 7 to 25% 
have been observed among female sex workers; the risk 
of positivity has been associated with the length of time 
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during which they have engaged in prostitution and 
with a history of chlamydia or syphilis infection.‘,’ Con- 
dom use has been shown to protect against HTLV-I 
acquisition among registered and clandestine female 
sex workers in Lima.‘,” Seropositivity rates of 4 to 14% 
for HTLV-I have been reported among bisexual or homo- 
sexual males and among people with a high number of 
sexual partners who are treated for sexually transmit- 
ted diseases.6 
Studies conducted among general populations in 
Caribbean countries have shown that the presence of 
HTLV-I correlates with age (>40 years), female gender, 
especially among those of low socioeconomic status, and 
a history of blood transfusion.” In one recent study con- 
ducted in 568 asymptomatic women older than 20 years 
of age who were randomly selected from three Peruvian 
regions, 2.6% were positive for HTLV-I antibody. The his- 
tory of blood transfusion was one of the most important 
factors and was significantly associated with HTLV-I in 
that 13.6% of people who had received blood transfu- 
sions were HTLV-I positive (P < 0.00002) compared to 
1.2% who had no blood transfusion history.r2 
Human Tcell lymphotropic virus-type I infection has 
been associated with several diseases, among them, trop- 
ical spastic paraparesia (TSP) or HTLV-I-associated 
myelopathy (HAM); both TSP and HAM have been fre- 
quently reported in Colombia, Brazil, Argentina, Chile, 
and Peru.‘3-‘6 In these cases, 25 to 40% of patients had a 
history of blood transfusions, similar to the values 
reported in Martinique and Japan. In 1986, in HAM or 
TSP patients in Kagoshima, 39% had a history of a blood 
transfusion, whereas in the control group (without 
HAM/TSP) only 3.3% had such a history (p c O.OOl).” In 
these cases, the incubation period was shorter, and there 
was an early initiation of a progressive and irreversible 
neurologic pattern. Patients who acquire HTLV-I through 
nursing and then develop TSP have a longer incubation 
period of 20 to 30 years. In another series from Japan, 20% 
(26/129) of TSP or HAM cases had a history of blood 
transfusion opposed to only 3% (41/1290) in a healthy 
control group (odds ratio [OR] = 7.7; P < O.Ol).l” 
Another disease associated with HTLV-I infection is 
acute T-cell leukemia-lymphoma (ATLL). This association 
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also has been reported in Latin American countries’9 1n 
Peru, 10% of non-Hodgkin’s lymphomas are associated 
with HTLV-I.*O The influence of a history of blood 
transfusion is not clear in this disease, and its role has 
not been demonstrated in ATLL. 
Other infections, such as disseminated strongyloidi- 
asis, have been associated with HTLV-I infection. Among 
patients without other evident risk factors, Strongyloides 
stercorulis hyperinfection syndrome has been associated 
with HTLV-I in 87% of cases. Of these patients, 33% had 
a history of blood transfusion, which is significantly 
higher than among the general population.21 Several med- 
ical syndromes have been associated with HTLV-I with 
less frequency (e.g., pneumocystis pneumonia, Norwe- 
gian scabies, uveitis) but the role of blood transfusions in 
these cases has not been defined. 
Seropositivity rates for HTLV-I among blood donors 
in Latin America is estimated to be 0.1 to 2%. One early 
study in Buenos Aires found that only 4 of 12,846 donors 
were positive; however, eight additional patients were pos- 
itive by enzyme-linked immunosorbent assay (ELISA) and 
indeterminant by Western blot.22 In northern Argentina 
(Jujuy) the rate recently detected was 0.81% (39/4805).23 
In Sao Paulo, in one early study, HTLV-I positivity of 0.15% 
in 17,063 donors was detected.24 Recently, in Bello Hor- 
izonte, 689 (1.35%) of 51,135 blood donors were posi- 
tive.z5 In a national survey in 1995 in Brazil, the overall 
positivity among donors was 1%.26 
In trials in Paraguay, Chile, and Cali, Colombia, rates 
of 1.1% (7/621), 0.7% (7/954), and 0.7% (91/13,000), 
respectively, were found in healthy blood donors.27,28 
In Peru, during 1997, Fuentes conducted a survey of 
the National Program of Blood Banks. In 164 different 
blood banks, they tested 142,583 donors; 2,068 (1.45%) 
were positive for HTLV-I at screening, and 1,86 1 (1.3%) 
were confirmed positive on re-testing.z9 According to 
national guidelines, screening for HTLV-1 is mandatory in 
all Peruvian blood banks. 
In the United States, in one trial with 39,898 blood 
donors, 10 (0.025%) were positive, and because of this 
low rate, universal screening for HTLV-I has been con- 
ducted since 1988. In Japan for all individuals donating 
whole blood or cellular compounds, the Japanese Red 
Cross started to systematically screen blood, and after 
2 years with these national guidelines, the number of 
reported patients with HAIvI/TSP has decreased by 16%.‘8 
In France and other European countries, blood screen- 
ing was started in 1991. In developing countries under 
economic restrictions, a selection of endemic areas, eth- 
nic groups, and populations with high-risk sexual behav- 
ior could be made for screening specific populations, to 
control costs; however, intra-country and inter-country 
migration supports a more global policy of recommen- 
dation of HTLV-I screening, as performed in Japan, the 
United States, and Europe, where the HTLV-I infection 
rate is low. 
It is evident that each country should be responsi- 
ble for identifying endemic areas, affected ethnic groups, 
and regions within its borders where ELISA for HTLV-I 
should be mandatory. On the basis of updated data on 
HTLV-I infection, Latin American and Caribbean coun- 
tries are areas where HTLV-I screening in blood banks is 
recommended. 
With the new highly sensitive ELISA for HTLV-I, it is 
easy to identify infected donors, but the results need to 
be confirmed by Western blot before donors are identified 
as seropositive cases. Screening of all family members to 
whom transmission has been possible through breast feed- 
ing or sexual intercourse is recommended. In family sur- 
veys of index cases (strongyloidiasis or TSP with HLW-I) 
20 to 28% of the members infected with HTLV-I were 
detected (Gotuzzo E. Unpublished data). This screening 
procedure will avoid new cases and permit an early diag- 
nosis of some HTLV-I-associated diseases. 
Consideration should be given to the following: 
l Although ELISA tests for screening are sensitive, they 
are not specific, and produce 2 to 10% false-positive 
results that require a second test and a Western blot, 
which makes the system more expensive. 
. Important issues are the emotional reactions and 
counselling required by HTLV-I-seropositive blood 
donors (only in the cases that are confirmed by 
Western blot). Usually, people with anxiety or depres- 
sion attributable to the diagnosis need to receive 
counselling support for 3 to 5 weeks. The counselling 
needs to be continuous, with new information regard- 
ing ways to reduce transmission provided to stable 
partners and women of childbearing age, according 
to each case. Human T-cell lymphotropic virus-type I 
should be clearly differentiated from HIV 
. The absence of documented available treatment for 
HTLV-I and the risk of developing a disease during a 
lifetime of 1 to 4% for TSP and 1 to 2% for ATLL also 
produces anxiety, especially because the risk factors 
that trigger the appearance of these diseases are not 
known. However, an early diagnosis can help in the 
treatment of HTLV-I-associated diseases, and effective 
treatment for HTLV-I itself may be available in the 
future. 
. It is important to have policies to prevent the trans- 
mission of HTLV-I infection, and it is recommended 
that discordant partners use condoms. 
A special comment should be made for ELISA-positive 
patients with an indeterminate Western blot. Although 
some authors do not include these patients in the num- 
ber of infected, the use of their donated blood should be 
avoided and these patients should be clinically and sero- 
logically studied every 6 months until their final status is 
defined. One International Reference Center should be 
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established to follow these cases for a better defmition 
of the outcome of such individuals. 
Although more HTLV-I infections are attributable to 
transmission through breast feeding and sexual inter- 
course, it is imperative to reduce transmission from blood 
products. A cost:benefits analysis of screening for HTLV-I 
in blood donors needs to be done country-by-country. 
The specter of infecting blood product recipients with a 
tumor or paraparesia causing virus must be included in 
this analysis. 
In conclusion, the risk of transmission of HTLV-I by 
transfusion, particulary in Latin America and the Caribbean, 
makes it important that blood banks screen for HTLV-I. 
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